

VEGA DAILY

Unlock Your Best Quote
Ask VEGA Now!

October 13, 2026

VITAMIN

01

- On October 12, Redpont Biotechnology adjusted its latest Nicotinamide quotation to USD5.95/kg, citing continued increases in upstream raw material prices and higher production costs.
- Jiangxi Brother Pharmaceutical Co., Ltd. received environmental approval for two vitamin-related projects in Jiangxi, with a combined investment of approximately USD 85.52 million. The projects cover a new Vitamin B3 and supporting products project and technical upgrades to existing vitamin and catalytic materials facilities, with no change in total capacity or product range

AMINO ACID

02

- EFSA confirmed that fermentation-derived L-Valine, produced using Escherichia coli CCTCC M 2022134, is safe and effective as a nutritional feed additive for all animal species at appropriate inclusion levels.
- On October 5, 2026, the U.S. Department of Commerce finalized expedited sunset reviews of anti-dumping duties on Methionine from France, Japan, and Spain. If the duties are revoked, estimated dumping margins would be 43.82%, 76.50%, and 37.53%, respectively. Together with the CJ-ADM joint venture in North America, the developments signal shifts in the regional amino acid market.

API

03

- The environmental assessment approval documents for Zhejiang Shenzhou Pharmaceutical Co., Ltd.'s technical upgrade project involving 2 MT/year of Dydrogesterone, along with production and packaging layout optimization for 150 MT/year of Spironolactone and 5 MT/year of Testosterone, were publicly disclosed for public consultation. The public consultation period runs from October 10 to 16, 2026.
- On October 12, Fuan Pharmaceutical announced that its wholly owned subsidiary, Fuan Pharmaceutical Group Chongqing Bosheng Pharmaceutical Co., Ltd., had received a chemical API marketing approval notice from the NMPA for Cefazolin Sodium. The registration number is Y20240001556.

FOOD ADDITIVE

04

Bloomage Biotechnology Corporation Limited is expanding its bioactive ingredient portfolio beyond Hyaluronic Acid to include PDRN/PN, recombinant Collagen, human milk oligosaccharides (HMOs), L-Ergothioneine, and Salidroside. Some products have entered commercialization and begun contributing revenue, with PDRN and recombinant Collagen emerging as new growth drivers in its raw material business.

Reported by Shea, Sharon and Faye

ONE STOP SOLUTION SUPPLIER



www.vegapharma.com



www.vegafeed.com



www.prumix.com

